Parenteral nitrogen mustard for inflammatory arthritis

Author and Disclosure Information


A patient with progressive psoriatic arthritis refractory to methotrexate therapy was treated empirically with intravenous nitrogen mustard, or HN2. His response to therapy was compared with the responses of five rheumatoid arthritis patients treated with the same regimen. At 14 days after therapy was begun the patient with psoriatic arthritis showed significant improvement, at least comparable to that observed in the rheumatoid arthritis group. Intravenous HN2 therapy may be an alternative to methotrexate for progressive psoriatic arthritis.



Next Article: